Cover Image
市場調查報告書

市場進入的課題:腎細胞癌 (歐盟5國)

Market Access Impact (EU5) [RCC]

出版商 FirstWord 商品編碼 509315
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
市場進入的課題:腎細胞癌 (歐盟5國) Market Access Impact (EU5) [RCC]
出版日期: 2017年05月01日 內容資訊: 英文
簡介

本報告提供以150名歐盟5國 (法國·義大利·德國·西班牙·英國)癌症專門醫生為對象之腎細胞癌治療藥的處方趨勢調查,進行打入市場的各種障礙與對處方的影響,及主要9種品牌藥的處方相關比較分析·個別分析。

調查對象

  • Afinitor (Everolimus:Novartis)
  • Avastin (Bevacizumab:Roche)
  • Cabometyx (Cabozantinib:Exelixis/Ipsen)
  • Inlyta (Axitinib :Pfizer)
  • Nexavar (Sorafenib:Bayer)
  • Opdivo (Nivolumab:Bristol-Myers Squibb)
  • Sutent (Sunitinib:Pfizer)
  • Torisel (Temsirolimus:Pfizer)
  • Votrient (Pazopanib:Novartis)

調查課題

  • 各種障礙對打入市場的影響
    • 醫生開出最多的品牌?
    • 市場障礙如何影響處方決定?
    • 哪些障礙影響最大?
  • 各品牌的障礙的影響
    • 有多少醫生開出你的品牌?有多少沒有但會考慮?
    • 為什麼醫生不開出你的品牌?他們以何種取代?
    • 互爭市佔率的競爭品牌為何?
目錄

Eliminating market barriers could help one brand almost double its market share

Market barriers have a modest but significant effect on renal cell carcinoma (RCC) prescriptions in the EU5. The brands that can find a way to eliminate them stand to make important share gains. Especially in the middle of the market, where competition is lively, and at the bottom of the market, where one brand is poised to nearly double its market share.

Find out which barriers are costing your brand market share Market Access Impact: RCC (EU5) .

Based on a survey of 150 medical oncologists, the report covers 9 major therapies from Bayer, Bristol-Myers Squibb, Exelixis, Ipsen Novartis, Pfizer, and Roche. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Top Takeaways

  • The top three barriers affect the market equally: Together they're responsible for half of the overall impact on prescriptions.
  • Eliminating barriers would shake up the middle of the market: The fourth and fifth place brands would each drop by two spots to sixth place and seventh place respectively.
  • Barriers are keeping one brand stuck in last place: Significantly more doctors experience barriers with this brand. If barriers didn't exist, its market share would double.
  • Many doctors may not see the problem: 55 percent or more of them don't experience any barriers with most of the surveyed brands.
  • Doctors are open to alternatives: 80% or more of surveyed doctors either prescribe, or would consider prescribing all of the surveyed brands.
  • One brand has a big perception problem: Every doctor has heard of it, but nearly 20% say they wouldn't prescribe it.

Insight into 9 Major RCC Drugs

  • Afinitor (everolimus; Novartis)
  • Avastin (bevacizumab; Roche)
  • Cabometyx (cabozantinib; Exelixis/Ipsen)
  • Inlyta (axitinib; Pfizer)
  • Nexavar (sorafenib; Bayer)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Sutent (sunitinib; Pfizer)
  • Torisel (temsirolimus; Pfizer)
  • Votrient (pazopanib; Novartis)

Exploring Market Access Barriers

Market Access Impact: RCC (EU5) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical oncologists-30 from each EU5 country (France, Italy, Germany, Spain, UK) -chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with RCC in total in the last month

We conducted the survey between April 3rd and 7th, 2017.

Back to Top